Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera.

New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark’s Novo Nordisk, over a bid for Metsera that Novo announced Thursday.

Novo said it planned to buy Metsera in a deal that could be worth up to $9 billion, and Metsera said the offer appeared to be superior to Pfizer’s bid, which was announced in September.

Metsera Inc. has no products on the market, but it is developing potential oral and injectable treatments. That includes some potential treatments that could target lucrative fields for obesity and diabetes.

Novo already has the treatments Wegovy and Ozempic on the market in those respective categories.

Pfizer said th

See Full Page